NZ622713A - Combination cancer therapy with hsp90 inhibitory compounds - Google Patents

Combination cancer therapy with hsp90 inhibitory compounds

Info

Publication number
NZ622713A
NZ622713A NZ622713A NZ62271310A NZ622713A NZ 622713 A NZ622713 A NZ 622713A NZ 622713 A NZ622713 A NZ 622713A NZ 62271310 A NZ62271310 A NZ 62271310A NZ 622713 A NZ622713 A NZ 622713A
Authority
NZ
New Zealand
Prior art keywords
cancer therapy
inhibitory compounds
hydroxy
combination cancer
hsp90 inhibitory
Prior art date
Application number
NZ622713A
Inventor
Kevin Paul Foley
David Proia
Ronald K Blackman
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of NZ622713A publication Critical patent/NZ622713A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

622713 Disclosed is a method for treating a subject with a cancer selected from breast cancer, ovarian cancer and prostate cancer, comprising administering to the subject an effective amount of paclitaxel or docetaxel and an effective amount of: 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole or 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate a tautomer, or a pharmaceutically acceptable salt thereof.
NZ622713A 2009-10-19 2010-10-19 Combination cancer therapy with hsp90 inhibitory compounds NZ622713A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27933009P 2009-10-19 2009-10-19
US33577810P 2010-01-11 2010-01-11
NZ599445A NZ599445A (en) 2009-10-19 2010-10-19 Combination cancer therapy with hsp90 inhibitory compounds

Publications (1)

Publication Number Publication Date
NZ622713A true NZ622713A (en) 2015-07-31

Family

ID=43218142

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ622713A NZ622713A (en) 2009-10-19 2010-10-19 Combination cancer therapy with hsp90 inhibitory compounds
NZ599445A NZ599445A (en) 2009-10-19 2010-10-19 Combination cancer therapy with hsp90 inhibitory compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ599445A NZ599445A (en) 2009-10-19 2010-10-19 Combination cancer therapy with hsp90 inhibitory compounds

Country Status (21)

Country Link
US (1) US20120245186A1 (en)
EP (1) EP2490688B1 (en)
JP (2) JP2013508378A (en)
KR (1) KR20120093970A (en)
CN (1) CN102695504A (en)
AU (1) AU2010308306A1 (en)
BR (1) BR112012009215A2 (en)
CA (1) CA2779233A1 (en)
CY (1) CY1115902T1 (en)
DK (1) DK2490688T3 (en)
EA (1) EA022119B1 (en)
ES (1) ES2526566T3 (en)
HK (1) HK1175112A1 (en)
HR (1) HRP20141150T1 (en)
MX (1) MX2012004577A (en)
NZ (2) NZ622713A (en)
PL (1) PL2490688T3 (en)
PT (1) PT2490688E (en)
RS (1) RS53716B1 (en)
SI (1) SI2490688T1 (en)
WO (1) WO2011049946A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5178515B2 (en) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Pyrazole compounds that modulate Hsp90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
TW200800260A (en) 2006-05-25 2008-01-01 Synta Pharmaceuticals Corp Method for treating proliferative disorders associated with protooncogene products
AU2007267859B2 (en) 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
CA2653336C (en) 2006-05-25 2014-10-28 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
WO2009139916A1 (en) * 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
US8450500B2 (en) 2008-06-04 2013-05-28 Synta Pharmaceuticals Corp. Pyrrole compounds that modulate HSP90 activity
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
WO2010017479A1 (en) * 2008-08-08 2010-02-11 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
KR20120117905A (en) 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Compositions and methods for enhancing proteasome activity
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
AU2011255438A1 (en) * 2010-05-20 2013-01-10 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
US20130172333A1 (en) * 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
EP2575810A1 (en) * 2010-05-24 2013-04-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2012037072A1 (en) * 2010-09-13 2012-03-22 Synta Pharmaceuticals Corporation Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients
CN103635230B (en) 2011-05-12 2017-10-31 普罗蒂斯特斯治疗公司 Albumen homeostasis conditioning agent
EP2714039A1 (en) * 2011-05-23 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
WO2012162372A1 (en) * 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
WO2012162584A1 (en) * 2011-05-26 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
AU2012280931A1 (en) 2011-07-07 2014-02-27 Synta Pharmaceuticals Corp. Treating cancer with HSP90 inhibitory compounds
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
AU2012332421A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors
WO2013074594A1 (en) * 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
RU2719422C2 (en) 2014-08-04 2020-04-17 Нуэволюшон А/С Optionally condensed heterocyclyl-substituted pyrimidine derivatives suitable for treating inflammatory, metabolic, oncological and autoimmune diseases
CN108026136A (en) 2015-08-06 2018-05-11 奇默里克斯公司 Pyrrolopyrimidine nucleosides as useful antivirotic and the like
CN105237533B (en) * 2015-10-26 2017-03-22 中国药科大学 Tetrahydropyridine [4,3-d] miazines Hsp90 inhibitor and medical application thereof
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
ME01498B (en) 2004-11-18 2014-04-20 Synta Pharmaceuticals Corp Triazole compounds that modulate hsp90 activity
TW200800260A (en) * 2006-05-25 2008-01-01 Synta Pharmaceuticals Corp Method for treating proliferative disorders associated with protooncogene products
DE102007002715A1 (en) * 2007-01-18 2008-07-24 Merck Patent Gmbh triazole
EP2133094A4 (en) * 2007-03-05 2010-10-13 Kyowa Hakko Kirin Co Ltd Pharmaceutical composition
WO2009002321A1 (en) 2007-06-27 2008-12-31 Thomson Licensing Enhancing image quality
BRPI0815116A2 (en) * 2007-08-13 2015-01-27 Synta Pharmaceuticals Corp Triazole Compounds That Modulate HSP90 Activity
AU2012280931A1 (en) * 2011-07-07 2014-02-27 Synta Pharmaceuticals Corp. Treating cancer with HSP90 inhibitory compounds

Also Published As

Publication number Publication date
PT2490688E (en) 2014-12-29
PL2490688T3 (en) 2015-03-31
CA2779233A1 (en) 2011-04-28
HK1175112A1 (en) 2013-06-28
EP2490688B1 (en) 2014-10-08
RS53716B1 (en) 2015-04-30
ES2526566T3 (en) 2015-01-13
US20120245186A1 (en) 2012-09-27
JP2016041715A (en) 2016-03-31
WO2011049946A1 (en) 2011-04-28
BR112012009215A2 (en) 2019-09-24
KR20120093970A (en) 2012-08-23
MX2012004577A (en) 2012-06-13
EA022119B1 (en) 2015-11-30
SI2490688T1 (en) 2015-01-30
NZ599445A (en) 2014-04-30
EA201270570A1 (en) 2012-09-28
JP2013508378A (en) 2013-03-07
AU2010308306A1 (en) 2012-05-10
DK2490688T3 (en) 2014-12-08
EP2490688A1 (en) 2012-08-29
HRP20141150T1 (en) 2015-01-30
CY1115902T1 (en) 2017-01-25
CN102695504A (en) 2012-09-26

Similar Documents

Publication Publication Date Title
NZ622713A (en) Combination cancer therapy with hsp90 inhibitory compounds
MX2020010496A (en) Inhibitors of lysine specific demethylase-1.
MX2010001565A (en) Triazole compounds that modulate hsp90 activity.
BRPI0518315A2 (en) thiazole compounds that modulate hsp90 protein activity, associated inhibition, treatment and induction methods and pharmaceutical composition
MX2017010299A (en) Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer.
WO2005123104A3 (en) Use of vegf inhibitors for the treatment of human cancer
NZ710355A (en) Diarylhydantoin compounds
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
WO2012078757A3 (en) Combination for breast cancer therapy with hsp90 inhibitory compounds
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
UA109271C2 (en) Combination of phytocannabinoids and temosolamide for treating glioma
TN2010000071A1 (en) Fused imidazoles or cancer treatment
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
MX336710B (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases.
TW200800975A (en) New compounds 2
GEP20146138B (en) Method for treating androgen receptor positive cancers
WO2012141796A3 (en) Prostate cancer therapy with hsp90 inhibitory compounds
EA200900913A1 (en) TRIAZOLE DERIVATIVE AS A HSP90 INHIBITOR
WO2009048958A3 (en) Methods and compositions involving chitosan nanoparticles
WO2009066060A3 (en) 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use
WO2007108947A3 (en) Nitrofuran compounds for the treatment of cancer and angiogenesis
MX2016014365A (en) Combination therapies targeting mitochondria for cancer therapy.
MX2009009816A (en) Monoclonal antibodies for treatment of cancer.
TNSN07294A1 (en) Treatment of metastasized tumors
MX2011011687A (en) Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 OCT 2017 BY DAVIES COLLISON CAVE

Effective date: 20151104

LAPS Patent lapsed